AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Inclusion Criteria

• •Patients must have histologically or cytologically confirmed AML other than acute promyelocytic leukemia (2008 World Health Organization (WHO) classification)
• •Patients age \>= 60 years with less than two prior treatment regimens not candidates for or have refused standard chemotherapy, excluding subjects with acute promyelocytic leukemia (APL) or with favorable cytogenetic abnormalities \[inv16, t(8;21)\]
• •Patient at the time of enrollment should not be a candidate for allogeneic stem cell transplantation
• •The Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
• •Serum creatinine or calculated creatinine clearance =\< 1.5 \* upper limit of normal (ULN) OR \>= 60 mL/min for patients with creatinine levels \> 1.5 \* institutional ULN
• •Serum total bilirubin =\< 2 \* ULN OR direct bilirubin =\< ULN for patients with total bilirubin levels \> 2 \* ULN, unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis
• •asparate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT /SGPT) =\< 2.5 \* ULN or =\< 5 \* ULN unless considered to be secondary to leukemic involvement
• •Fasting serum glucose =\< 150 mg/dl
• •HBA1c =\< 9%
• •Female patient of childbearing potential must have a negative serum or urine pregnancy test beta- Human chorionic gonadotropin (hCG) within 72 hours prior to receiving the first dose of study medication; the effects of MK-2206 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treatment physician immediately
• •Patient, or the patient"s legal representative, has voluntarily agreed to participate by giving written informed consent
• •Patient is able to swallow tablets and has no surgical or anatomical condition that will preclude the patient from swallowing and absorbing oral medications on an ongoing basis